CURIS INC (NASDAQ: CRIS), a Phase 2 oncology biotech developing emavusertib for chronic lymphocytic leukemia, has a pending supply overhang that dwarfs its current tradeable shares. The October 2026 PIPE — a private placement in which investors buy shares directly from the company — sold 16,666,680 shares and pre-funded warrants at $0.51 each, plus another 16,666,680 common warrants exercisable at $0.60. That single deal represents roughly 33.3 million shares, about six times the company's estimated 5.47-million-share public float.
Those shares cannot trade freely yet. Under the deal terms, Curis must file a resale registration — a filing that allows PIPE buyers to sell their shares on the open market — by approximately November 18, 2026. If it misses the deadline, the company owes liquidated damages of 1% every 30 days. Effectiveness is expected around December, which coincides with the company's planned CLL clinical data readout.
The float is already larger than it looks
Popular data feeds report the float at roughly 1.73 million shares. That figure is stale. It misses 335,001 shares from the August 2026 offering and approximately 3.4 million pre-funded warrants — near-zero-strike instruments that function almost identically to common stock — that appear to have been exercised since. ShareStructure's reconstruction puts the real tradeable float at about 5.47 million shares, or 81.8% of 6,679,229 shares outstanding.
More overhang is already live
Beyond the unregistered PIPE shares, 4,860,010 existing warrants were repriced to $0.60 as part of the October deal. These are exercisable immediately and already registered, meaning the underlying shares go straight to market on exercise. That block alone equals roughly 89% of the current float.
The company has 567.5 million shares authorized against only 6.68 million outstanding. It has room to issue.
A pattern, not an event
Six dilutive raises in 24 months tell the story. Split-adjusted offering prices have fallen from $100.90 to $48.20, $45.50, $15.00, $1.50, and now $0.51 — each accompanied by 100% to 300% warrant coverage. The August and October deals were placed by the same agents, A.G.P. and Laidlaw, just nine weeks apart. Three reverse splits totaling 2,000-to-1 since 2018 have compressed the share count each time, only for new issuance to re-expand it. Split-adjusted shares outstanding grew approximately 933% over the trailing twelve months.
Management has disclosed that the October proceeds fund operations only through the December data readout. Cash on hand stood at $5.1 million against a quarterly burn of roughly $9 million, implying another financing likely in the first quarter of 2027.
What the 8/10 score reflects
ShareStructure assigns CRIS a dilution risk score of 8 out of 10. The score is driven by near-term supply mechanics: up to roughly 21.7 million shares could reach the float within 90 days — nearly four times the current tradeable supply — and about 38.8 million within twelve months. There are no toxic convertible notes or variable-rate instruments in the capital structure. The risk is straightforward volume: fixed-price paper stacked so deep against a small float that the timing of registration effectiveness and warrant exercises becomes the central structural variable. The next key date is the November 18 resale-registration filing deadline.